{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:39:49Z","timestamp":1794868789940,"version":"4.9.1"},"reference-count":15,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":11534,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1981,8,9]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Using the hot plate test, the potency and mechanism of the analgesic activity of levonantradol was studied in mice. Levonantradol is 10 to 30 times more potent than morphine; the antinociception can be only partially blocked by naloxone. Similar limited antagonism by cholinergics indicates possible opiodergic mechanism. The role of serotoninergic pathways is unclear; antinociception is partially blocked by 5,7\u2010dihydroxytryptamine, unaffected by <jats:italic>p<\/jats:italic>\u2010chlorophenylalanine, and potentiated by cyproheptadine. Levonantradol blocks naloxone\u2010induced signs of abstinence in morphine\u2010dependent mice, being 3000 times more potent than morphine and 300 times more potent than \u0394<jats:sup>9<\/jats:sup>\u2010tetrahydrocannabinol (THC).<\/jats:p>","DOI":"10.1002\/j.1552-4604.1981.tb02611.x","type":"journal-article","created":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T01:35:12Z","timestamp":1362792912000},"source":"Crossref","is-referenced-by-count":27,"title":["A Pharmacological Analysis of Levonantradol Antinociception in Mice"],"prefix":"10.1002","volume":"21","author":[{"given":"JOSEPH J.","family":"JACOB","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KRISHNASWAMI","family":"RAMABADRAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARY","family":"CAMPOS\u2010MEDEIROS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-025488-3.50095-7"},{"key":"e_1_2_1_3_2","first-page":"243","article-title":"CP\u201044001, a novel benzo(c)quinoline analgesic","volume":"20","author":"Milne GM","year":"1978","journal-title":"Pharmacologist."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1981.tb02612.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00421535"},{"key":"e_1_2_1_6_2","first-page":"299","article-title":"Narcotic antagonists","volume":"8","author":"Jacob JJC","year":"1974","journal-title":"Adv Biochem Psychopharmacol."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1978.tb08645.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/267495a0"},{"key":"e_1_2_1_9_2","first-page":"45","volume-title":"La Douleur.","author":"Jacob J","year":"1979"},{"key":"e_1_2_1_10_2","article-title":"Role of opiate receptors and endogenous ligands in nociception","author":"Jacob JJC","journal-title":"J Pharmacol Therap. Part C."},{"key":"e_1_2_1_11_2","first-page":"27","article-title":"Facilitatory effect of naloxone and involvement of specific ligand\u2010opiate receptor system in the antinociceptive effects of non\u2010opioid drugs","volume":"236","author":"Ramabadran K","year":"1978","journal-title":"Arch Int Pharmacodyn Therap."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7433977"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02205223"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(76)90699-5"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1981.tb02609.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1981.tb02615.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1981.tb02611.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1981.tb02611.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:49:23Z","timestamp":1694584163000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1981.tb02611.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,8,9]]},"references-count":15,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1981,8,9]]}},"alternative-id":["10.1002\/j.1552-4604.1981.tb02611.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb02611.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,8,9]]}}}